Abstract
Purpose
[18F]AV-1451 is a positron emission tomography (PET) radioligand for detecting paired helical filament tau. Our aim was to estimate the radiation dose of [18F]AV-1451 in humans.
Procedures
Whole-body PET scans were acquired for six healthy volunteers (three male, three female) for 128 min after injection of [18F]AV-1451 (268 ± 31 MBq). Radiation doses were estimated using the OLINDA/EXM software.
Results
The estimated organ doses ranged from 7.81 to 81.2 μSv/MBq. The critical organ for radiation burden was the liver. Radiation doses to the reproductive and blood-forming organs were 14.15, 8.43, and 18.35 μSv/MBq for the ovaries, testes, and red marrow, respectively. The mean effective dose was 22.47 ± 3.59 μSv/MBq.
Conclusions
A standard single injection of 185 MBq (5 mCi) results in an effective dose of 4.7 mSv in a healthy subject. Therefore, [18F]AV-1451 could be used in multiple PET scans of the same subject per year.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buee L, Bussiere T, Buee-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130
Dani M, Edison P, Brooks DJ (2015) Imaging biomarkers in tauopathies. Parkinsonism Relat Disord 22:S26–S28
Chien DT, Szardenings AK, Bahri S et al (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38:171–184
Harada R, Okamura N, Furumoto S et al (2015) [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 42:1052–1061
Harada R, Okamura N, Furumoto S et al (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 40:125–132
Tago T, Furumoto S, Okamura N, et al. (2015) Preclinical evaluation of [18F]THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer. Mol Imaging Biol
Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P (2014) Developments in tau PET imaging. Can J Neurol Sci 41:547–553
Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468
Marquie M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800
Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108
Xia CF, Arteaga J, Chen G et al (2013) [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9:666–676
Shoup TM, Yokell DL, Rice PA et al (2013) A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Labelled Comp Radiopharm 56:736–740
Hines CS, Liow JS, Zanotti-Fregonara P et al (2011) Human biodistribution and dosimetry of 11C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 6:e25309
Zanotti-Fregonara P, Lammertsma AA, Innis RB (2013) Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 40:1781–1783
International Commission on Radiological Protection (1996) Radiological Protection and Safety in Medicine. Oxford
Acknowledgments
This research was supported by the Nuclear R&D Program of the National Research Foundation of Korea (Grant No. NRF-2015M2A2A7027110) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1C1A2A01054507). The authors express gratitude to Tae Ho Sung, Won Tak Lee and Min Soo Jeon who managed all PET scans.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Choi, J.Y., Lyoo, C.H., Lee, J.H. et al. Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology. Mol Imaging Biol 18, 479–482 (2016). https://doi.org/10.1007/s11307-015-0924-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-015-0924-7